A novel therapeutic fusion protein vaccine by two different families of heat shock proteins linked with HPV16 E7 generates potent antitumor immunity and antiangiogenesis

Vaccine

Volumn 26, Issue 10, 2008, Pages 1387-1396

  Liu, Bo ^a   Ye, Dongxia ^b   Song, Xinxin ^a   Zhao, Xinhua ^a   Yi, Linan ^a   Song, Jietao ^a   Zhang, Zhiyuan ^b   Zhao, Qingzheng ^a  

^a CANCER HOSPITAL   (China)

^b SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

Author keywords

Antiangiogenesis; Calreticulin; E7; Heat shock protein; HPV; Therapeutic vaccine

Indexed keywords

CALRETICULIN; HEAT SHOCK PROTEIN; PROTEIN E7; VIRUS FUSION PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTITUMOR GENE; ARTICLE; C57BL 6 MOUSE; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNE RESPONSE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TUMOR IMMUNITY; UTERINE CERVIX CANCER;

ALLANTOIN; ANIMALS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CHICKENS; CYTOTOXICITY TESTS, IMMUNOLOGIC; FEMALE; FLOW CYTOMETRY; HEAT-SHOCK PROTEINS; HUMAN PAPILLOMAVIRUS 16; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; INTERFERON TYPE II; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PLASMIDS; VACCINES, SYNTHETIC;

EID: 39249084560     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.12.034     Document Type: Article

References (42)

1. Saslow D., Castle P.E., Cox J.T., Davey D.D., Einstein M.H., Ferris D.G., et al. American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA Cancer J Clin 57 1 (2007) 7-28
2. Munoz N., Bosch F.X., de Sanjose S., Herrero R., Castellsague X., Shah K.V., et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348 6 (2003) 518-527
3. Parkin D.M., and Bray F. The burden of HPV-related cancers. Vaccine 24 Suppl. 3 (2006) S11-S25 [chapter 2]
4. Govan V.A. Strategies for human papillomavirus therapeutic vaccines and other therapies based on the e6 and e7 oncogenes. Ann NY Acad Sci 1056 (2005) 328-343
5. Einstein M.H., Kadish A.S., Burk R.D., Kim M.Y., Wadler S., Streicher H., et al. Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III. Gynecol Oncol 21 (2007) 21
6. Peng S., Trimble C., Wu L., Pardoll D., Roden R., Hung C.F., et al. HLA-DQB1*02-restricted HPV16 E7 peptide-specific CD4 + T-cell immune responses correlate with regression of HPV16-associated high-grade squamous intraepithelial lesions. Clin Cancer Res 13 8 (2007) 2479-2487
7. Hsieh C.J., Kim T.W., Hung C.F., Juang J., Moniz M., Boyd D.A.K., et al. Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin. Vaccine 22 29-30 (2004) 3993-4001
8. Davidson E.J., Faulkner R.L., Sehr P., Pawlita M., Smyth L.J., Burt D.J., et al. Effect of TA-CIN (HPV16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV16/18 E6E7). Vaccine 22 21-22 (2004) 2722-2729
9. Gomez-Gutierrez J.G., Elpek K.G., Montes de Oca-Luna R., Shirwan H., Sam Zhou H., and McMasters K.M. Vaccination with an adenoviral vector expressing calreticulin-human papillomavirus 16 E7 fusion protein eradicates E7 expressing established tumors in mice. Cancer Immunol Immunother 56 7 (2007) 997-1007
10. Qian X., Lu Y., Liu Q., Chen K., Zhao Q., and Song J. Prophylactic, therapeutic and anti-metastatic effects of an HPV16mE6Delta/mE7/TBhsp70Delta fusion protein vaccine in an animal model. Immunol Lett 102 2 (2006) 191-201
11. Walker K.B., Keeble J., and Colaco C. Mycobacterial heat shock proteins as vaccines: a model of facilitated antigen presentation. Curr Mol Med 7 4 (2007) 339-350
12. Michalak M., Corbett E.F., Mesaeli N., Nakamura K., and Opas M. Calreticulin: one protein, one gene, many functions. Biochem J 344 Pt 2 (December) (1999) 281-292
13. Cheng W.F., Hung C.F., Chen C.A., Lee C.N., Su Y.N., Chai C.Y., et al. Characterization of DNA vaccines encoding the domains of calreticulin for their ability to elicit tumor-specific immunity and antiangiogenesis. Vaccine 23 29 (2005) 3864-3874
14. Belli F., Testori A., Rivoltini L., Maio M., Andreola G., Sertoli M.R., et al. Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J Clin Oncol 20 20 (2002) 4169-4180
15. Nakamura K., Zuppini A., Arnaudeau S., Lynch J., Ahsan I., Krause R., et al. Functional specialization of calreticulin domains. J Cell Biol 154 5 (2001) 961-972
16. Pike S.E., Yao L., Jones K.D., Cherney B., Appella E., Sakaguchi K., et al. Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth. J Exp Med 188 12 (1998) 2349-2356
17. Pike S.E., Yao L., Setsuda J., Jones K.D., Cherney B., Appella E., et al. Calreticulin and calreticulin fragments are endothelial cell inhibitors that suppress tumor growth. Blood 94 7 (1999) 2461-2468
18. Zhou X., Qian X., Zhao Q., Lu Y., and Xiong M. Efficient expression of modified human papillomavirus 16 e6/e7 fusion protein and the antitumor efficacy in a mouse model. Biol Pharm Bull 27 3 (2004) 303-307
19. Feltkamp M.C., Smits H.L., Vierboom M.P., Minnaar R.P., de Jongh B.M., Drijfhout J.W., et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 23 9 (1993) 2242-2249
20. Blezinger P., Wang J., Gondo M., Quezada A., Mehrens D., French M., et al. Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene. Nat Biotechnol 17 4 (1999) 343-348
21. Du G.J., Lin H.H., Xu Q.T., and Wang M.W. Thalidomide inhibits growth of tumors through COX-2 degradation independent of antiangiogenesis. Vascul Pharmacol 43 2 (2005) 112-119
22. Xiao F., Wei Y., Yang L., Zhao X., Tian L., Ding Z., et al. A gene therapy for cancer based on the angiogenesis inhibitor, vasostatin. Gene Ther 9 18 (2002) 1207-1213
23. Chu N.R., Wu H.B., Wu T., Boux L.J., Siegel M.I., and Mizzen L.A. Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guerin (BCG) hsp65 and HPV16 E7. Clin Exp Immunol 121 2 (2000) 216-225
24. van der Burg S.H., Kwappenberg K.M., O'Neill T., Brandt R.M., Melief C.J., Hickling J.K., et al. Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens. Vaccine 19 27 (2001) 3652-3660
25. Wu P.C., Yang L.C., Kuo H.K., Huang C.C., Tsai C.L., Lin P.R., et al. Inhibition of corneal angiogenesis by local application of vasostatin. Mol Vis 11 (2005) 28-35
26. Ribatti D., and Vacca A. Models for studying angiogenesis in vivo. Int J Biol Markers 14 4 (1999) 207-213
27. Tufan A.C., and Satiroglu-Tufan N.L. The chick embryo chorioallantoic membrane as a model system for the study of tumor angiogenesis, invasion and development of anti-angiogenic agents. Curr Cancer Drug Targets 5 4 (2005) 249-266
28. Shen L., and Rock K.L. Priming of T cells by exogenous antigen cross-presented on MHC class I molecules. Curr Opin Immunol 18 1 (2006) 85-91
29. Rock K.L. Exiting the outside world for cross-presentation. Immunity 25 4 (2006) 523-525
30. Binder R.J., and Srivastava P.K. Peptides chaperoned by heat-shock proteins are a necessary and sufficient source of antigen in the cross-priming of CD8 + T cells. Nat Immunol 6 6 (2005) 593-599
31. Basu S., Binder R.J., Ramalingam T., and Srivastava P.K. CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin. Immunity 14 3 (2001) 303-313
32. Becker T., Hartl F.U., and Wieland F. CD40 an extracellular receptor for binding and uptake of Hsp70-peptide complexes. J Cell Biol 158 7 (2002) 1277-1285
33. Delneste Y., Magistrelli G., Gauchat J., Haeuw J., Aubry J., Nakamura K., et al. Involvement of LOX-1 in dendritic cell-mediated antigen cross-presentation. Immunity 17 3 (2002) 353-362
34. Papetti M., and Herman I.M. Mechanisms of normal and tumor-derived angiogenesis. Am J Physiol Cell Physiol 282 5 (2002) C947-C970
35. Moniz M., Yeatermeyer J., and Wu T.C. Control of cancers by combining antiangiogenesis and cancer immunotherapy. Drugs Today (Barc) 41 7 (2005) 471-494
36. Ma L., Luo L., Qiao H., Dong X., Pan S., Jiang H., et al. Complete eradication of hepatocellular carcinomas by combined vasostatin gene therapy and B7H3-mediated immunotherapy. J Hepatol 46 1 (2007) 98-106
37. Yao L., Pike S.E., Pittaluga S., Cherney B., Gupta G., Jaffe E.S., et al. Anti-tumor activities of the angiogenesis inhibitors interferon-inducible protein-10 and the calreticulin fragment vasostatin. Cancer Immunol Immunother 51 7 (2002) 358-366
38. Li L., Yuan Y.Z., Lu J., Xia L., Zhu Y., Zhang Y.P., et al. Treatment of pancreatic carcinoma by adenoviral mediated gene transfer of vasostatin in mice. Gut 55 2 (2006) 259-265
39. Jazowiecka-Rakus J., Jarosz M., Kozlowska D., Sochanik A., and Szala S. Combination of vasostatin and cyclophosphamide in the therapy of murine melanoma tumors. Acta Biochim Pol 54 1 (2007) 125-133
40. Yao L., Pike S.E., Setsuda J., Parekh J., Gupta G., Raffeld M., et al. Effective targeting of tumor vasculature by the angiogenesis inhibitors vasostatin and interleukin-12. Blood 96 5 (2000) 1900-1905
41. Salvetti M., Ristori G., Buttinelli C., Fiori P., Falcone M., Britton W., et al. The immune response to mycobacterial 70-kDa heat shock proteins frequently involves autoreactive T cells and is quantitatively disregulated in multiple sclerosis. J Neuroimmunol 65 2 (1996) 143-153
42. Lange-Asschenfeldt B., Velasco P., Streit M., Hawighorst T., Pike S.E., Tosato G., et al. The angiogenesis inhibitor vasostatin does not impair wound healing at tumor-inhibiting doses. J Invest Dermatol 117 5 (2001) 1036-1041